Daiichi Sankyo is a leader in the Japanese pharmaceuticals business. The company manufactures prescription drugs, including treatments for cardiovascular, bone and joint, autoimmune, metabolic, and infectious diseases. Top products include Olmetec for hypertension, Loxonin for inflammation, Efient for patients with acute coronary syndrome, and edoxaban to help prevent venous thromboembolism. Daiichi Sankyo also makes over-the-counter (OTC) and generic drugs through subsidiaries including Daiichi Sankyo Healthcare. Daiichi Sankyo's products are sold through medical representatives and distributors located around the globe.
The company operates in more than 20 countries in Europe, the Americas, and Asia. In 2014, Japan accounted for 60% of total revenue.
Its R&D network spans Japan, the US, Europe, India, and East Asia but is primarily based at four sites in Japan.
In fiscal 2015 (ended March), revenue declined 18% to ¥919.4 million due to a decline in overseas sales. Net income skyrocketed, though, rising 428% to ¥322 million.
Daiichi Sankyo invests in growth efforts in its core markets of Japan, the US, Europe, as well as emerging markets. Its acquisition strategy includes buying new products and drug candidates in addition to promising companies that have the potential to boost its existing portfolio. The company also partners with other pharmaceuticals to commercialize various products. For example, in 2015, it entered a co-commercialization agreement with AstraZeneca for MOVANTIK in the US.
In 2015 the company gained US approval for its SAVAYSA tablets, which prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. It also received approval in Japan to make and market Methylene Blue Injection for toxic methemoglobinemia. In Switzerland, it gained approval for Lixiana, another stroke and systemic embolism preventative. In 2014, Daiichi Sankyo launched its antiplatelet agent Efient Tablets in Japan.
Also in 2014, the company sold its stake in
Mergers and Acquisitions
The company acquired Ambit Biosciences in 2014; the deal added that firm's quizartinib candidate, which is in phase 3 trials for the treatment of leukemia.
Daiichi Sankyo was formed when
for more than $7 billion in 2005. The two companies merged their operations into the newly formed Daiichi Sankyo, creating a top pharmaceutical manufacturer in Japan. Since the merger, the company has focused primarily on prescription and consumer drugs and has been exiting its chemical and animal health operations.